There is a new trial at University of Pennsylvania where T-cells are modified with CRISPR to target NY-ESO-1 and to remove endogenous TCR and PD-1:
There is a new trial at University of Pennsylvania where T-cells are modified with CRISPR to target NY-ESO-1 and to remove endogenous TCR and PD-1: